Are you Dr. Foon?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Breakthrough Way
Las Vegas, NV 89135Phone+1 702-822-5373Fax+1 702-944-0451
Summary
- Dr. Kenneth Foon, MD is an oncologist in Las Vegas, Nevada. He is currently licensed to practice medicine in Nevada, New Jersey, and Florida.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1980- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1977 - 1979
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1976 - 1977
University of California (San Diego) Medical CenterInternship, Internal Medicine, 1972 - 1973
Wayne State University School of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1975 - 2021
NJ State Medical License 2010 - 2019
NV State Medical License 2008 - 2011
FL State Medical License 2008 - 2010
PA State Medical License 2003 - 2008
OH State Medical License 1999 - 2003
MD State Medical License 1974 - 1994- Join now to see all
Publications & Presentations
PubMed
- 77 citationsValidation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials.Carla Casulo, Jesse G. Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S. Hochster
Blood. 2021-10-06 - 23 citationsReduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chr...Anthony R. Mato, Kenneth A. Foon, Tatyana Feldman, Stephen J. Schuster, Jakub Svoboda
American Journal of Hematology. 2015-06-01 - 54 citationsA phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid...Mark Kirschbaum, Kenneth A. Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone
Leukemia & Lymphoma. 2014-02-24
Grant Support
- Core--Protocol Specific ResearchNational Cancer Institute2004–2008
- Ganglioside GD2 As Target For Immunotherapy In MelanomaNational Cancer Institute2003–2004
- Southwest Oncology GroupNational Cancer Institute1999–2001
- Antiidiotype Vaccine With IL2 For Advanced MelanomaNational Cancer Institute2000
- Antiidiotype Vaccine With IL2 For Advanced MelanomaNational Cancer Institute1998
- New Therapeutic Approaches To Breast CancerNational Cancer Institute1995–1997
- Anti Idiotype Vaccine For Breast CancerNational Cancer Institute1995–1997
- Southwest Oncology GroupNational Cancer Institute1994–1997
- Comparison Of Alum And Qs 21 Based Anti ID VaccinesNational Cancer Institute1996
- Planning Grants For Prospective Cancer CentersNational Cancer Institute1995–1996
- Monoclonal Antibody Therapy Of GI CancersNational Cancer Institute1992–1993
- Monoclonal Antibody Therapy Of GI CancersNational Cancer Institute1992
- Momoclonal Antibody Therapy Of GI CancersNational Cancer Institute1991–1992
- Validation Of An In Vitro Drug Sensitivity Assay For CLLNational Cancer Institute1990
- Mechanisms Of IFN Action In Hairy-Cell LeukemiaNational Cancer Institute1988
- Mechanism Of IFM Action In Hairy-Cell LeukemiaNational Cancer Institute1987
- Mechanisms Of IFN Action In Hairy-Cell LeukemiaNational Cancer Institute1986–1987
